Evidence map›Paper›PMID 39829457›Full record

ArticleACS omega2025

Development of a Simultaneous Analytical Method for Amines Corresponding to 10 Typical Nitrosamines.

Shohei Fukuda, Takehiro Hoshiyama, Kanako Kondo, Osamu Uchikawa

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shohei FukudaR&D Division, Analytical Technology Unit, API Analytical Development Department, Towa Pharmaceutical Co., Ltd., 7-1-3 Doi-cho, Amagasaki, Hyogo 660-0083, Japan.ORCID https://orcid.org/0009-0003-7514-2468
Takehiro HoshiyamaR&D Division, Analytical Technology Unit, API Analytical Development Department, Towa Pharmaceutical Co., Ltd., 7-1-3 Doi-cho, Amagasaki, Hyogo 660-0083, Japan.
Kanako KondoR&D Division, Analytical Technology Unit, API Analytical Development Department, Towa Pharmaceutical Co., Ltd., 26-7 Ichiban-cho, Kadoma, Osaka 571-0033, Japan.
Osamu UchikawaTowa Pharmaceutical Co., Ltd., 2-11 Shinbashi-cho, Kadoma, Osaka 571-8580, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulatory authorities in various countries have successively issued notices and guidance to pharmaceutical manufacturers and distributors to evaluate the risk of contamination of nitrosamines in pharmaceutical products and to take appropriate measures. Analysis of nitrosamines in pharmaceutical products is not easy due to the large number of foreign substances, and the risk of contamination is determined by first conducting a desk investigation of the manufacturing process of the APIs or pharmaceutical products. However, a desk investigation may miss the risk since this method is not based on actual measurements. Therefore, in addition to conventional desk-based investigation, a new method is required to pick up risks that cannot be covered by a desk investigation. Nitrosamines are known to be formed by the reaction of amines with nitrosating agents such as nitrite. In the case of small alkyl nitrosamines such as NDMA and NDEA, the origin of the amines is mostly residual amines in the APIs. Residual amines in the APIs are a potential nitrosamine contamination risk, although the extent of that risk has rarely been reported. In this study, we developed and validated a simultaneous analytical method for amines corresponding to 10 typical small alkyl nitrosamines. Good linearity was obtained in the range of 0.003 to 10 μg/mL for MPA, 0.003 to 2 μg/mL for DIPA and DBA, 0.003 to 1 μg/mL for MeP, DEA, EIPA, and DPA, and 0.003 to 0.2 μg/mL for DMA, MOR, and MBA. The limits of quantitation and detection were 0.003 and 0.001-0.003 μg/mL, respectively. The recovery rates ranged from 70 to 130% for 121 APIs and were more than 40% for 83 APIs. Repeatability was also good, with %RSD < 15%. Although the correlation between the amount of amines detected in the APIs and the nitrosamines in the pharmaceutical products is under investigation, we expect that this analytical method will be used to determine the residual amine contents in APIs and contribute to the risk assessment of the nitrosamine contamination.

Identifiers

PMID39829457
PMCPMC11740105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.